# Riva Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/riva-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.rivatherapeutics.com/
- Total disclosed funding: $3M
- Latest round: Series A (Jun 22, 2023)
- Investors on record: 2

## About

Based in California, US, and co-founded by Brion W. Murray (President and CSO), William C. Hahn, Andrew Aguirre, and Francisca Vazque in 2022, Riva Therapeutics operates as a biotechnology company developing transformative medicines for cancer patients. In June 2023, the firm raised approximately USD 3 million in series A funding led by investors Forward Equity Partners and Meritz Securities.

The company specializes in precision oncology and leverages deep knowledge of genomic dependencies to create a new generation of small molecule therapeutics that selectively target essential tumor cell processes beyond DNA damage repair. Riva’s precision lethal therapies aim to provide profound clinical activity, be well-tolerated, and substantially improve patient lives.

The company plans to utilize the June 2023 funding to develop anti-cancer drugs.

## Funding rounds

- Series A, Jun 22, 2023, $3M — Meritz Securities, Forward Equity Partners

## Investors

- Meritz Securities — Series A
- Forward Equity Partners (https://capitalatlas.ai/funds/forward-equity-partners) — Series A